abbvie

EFPIA Disclosure Code
2019 Self-Certification Scheme

Healthcare professionals (HCPs) and healthcare organisations (HCOs) with whom AbbVie works provide the Pharmaceutical Industry with valuable, independent and expert knowledge derived from their clinical and management experience. As owners of scientific knowledge and experts in medicinal products, pharmaceutical companies can be a unique resource to the healthcare systems and providers, which will ultimately benefit the patients.

Throughout the medicines life cycle pharmaceutical companies work with scientists and HCPs. These collaborations are essential in addressing patient needs. Industry and HCPs collaborate in a range of activities from clinical research to sharing best clinical practice and exchanging information on how new medicines fit into the patient pathway.

EFPIA and its member associations have adopted codes and guidelines to ensure that the interactions of their member companies with HCPs and HCOs meet the high standards of integrity and transparency. Building greater transparency to the relationships between pharmaceutical companies and HCPs/HCOs aims to building understanding of the collaboration and recognition of its value to patient care.

Except in countries where disclosure is prescribed by laws, AbbVie hereby confirms that its disclosures of transfers of value (ToV) to HCPs and HCOs made in 2018 have been reported in application of the EFPIA Disclosure Code following key principles:

Disclosure quality

AbbVie certifies that:

- Its disclosures are made in each country where reportable ToV have been made;
- Its disclosures include direct and indirect ToV, as defined in the codes and associated guidance issued by EFPIA;
- Its Methodological Note describes the process it has followed in order to compile the data hereby disclosed.

Methodology used for the collection and organisation of ToV is in line with the EFPIA Disclosure Code's requirements and applicable codes

AbbVie certifies that:

- Data collection complies with the requirements of the EFPIA Disclosure Code;
- Actions were taken to encourage individual disclosure for HCPs' and HCOs' Transfers of Value (each as defined in the EFPIA Disclosure Code).

AbbVie
1 North Waukegan Road
North Chicago, IL 60064

Aggregate disclosures are limited to Research and Development ToV and such ToV that cannot be disclosed on an individual basis for legal reasons

AbbVie certifies that aggregate disclosure is limited to the following topics:

- Research and Development Transfers of Value (as defined in the EFPIA Disclosure Code);
- Transfers of Value to Recipients that have opposed to the publication on grounds of the protection of their private data;
- If an HCP or HCO (where applicable) has provided consent to individual disclosure only in respect of part of the Transfers of Value he/she/it received, all Transfers of Value to such HCP or HCO (where applicable) are being disclosed in the aggregate sections.

Ensuring compliance with Data Privacy Obligations

AbbVie certifies that its disclosure complies with the applicable privacy and data protection law.

Date: May 22, 2019

Name of signatory: Carlos Alban

Position in the Company: Vice Chairman, Chief Commercial Officer

Signature: 

almirall
feel the science

EFPIA Disclosure Code
2019 Self-Certification Scheme

Healthcare professionals (HCPs) and healthcare organisations (HCOs) with whom Almirall works provide the Pharmaceutical Industry with valuable, independent and expert knowledge derived from their clinical and management experience. As owners of scientific knowledge and experts in medicinal products, pharmaceutical companies can be a unique resource to the healthcare systems and providers, which will ultimately benefit the patients.

Throughout the medicines life cycle pharmaceutical companies work with scientists and HCPs. These collaborations are essential in addressing patient needs. Industry and HCPs collaborate in a range of activities from clinical research to sharing best clinical practice and exchanging information on how new medicines fit into the patient pathway.

EFPIA and its member associations have adopted codes and guidelines to ensure that the interactions of their member companies with HCPs and HCOs meet the high standards of integrity and transparency. Building greater transparency to the relationships between pharmaceutical companies and HCPs/HCOs aims to building understanding of the collaboration and recognition of its value to patient care.

Except in countries where disclosure is prescribed by laws, Almirall hereby confirms that its disclosures of transfers of value (ToVs) to HCPs and HCOs made in 2018 have been reported in application of the EFPIA Disclosure Code following key principles:

Disclosure quality

Almirall certifies that:

- Its disclosures are made in each country where it operates;
- Its disclosures include direct and indirect ToVs, as defined in the codes and associated guidance issued by EFPIA;
- Its Methodological Note describes the process it has followed in order to compile the data hereby disclosed.

Almirall, S.A.
Rda. General Mitre, 151
08022 Barcelona, Spain
P +34 93 291 30 00
F +34 93 291 31 80
almirall.com

Methodology used for the collection and organisation of ToVs is in line with the EFPIA Disclosure Code's requirements and applicable codes

Almirall certifies that:

- Data collection complies with the requirements of the EFPIA Disclosure Code;
- Actions were taken to ensure individual disclosure for HCPs and HCOs' transfers of values (each as defined in the EFPIA Disclosure Code).

Aggregate disclosures are limited to Research and Development ToVs and such ToVs that cannot be disclosed on an individual basis for legal reasons

Almirall certifies that aggregate disclosure is limited to the following topics:

- Research and Development Transfers of Value (as defined in the EFPIA Disclosure Code);
- Transfers of Value to Recipients that have opposed to the publication on grounds of the protection of their private data;
- If an HCP or HCO (where applicable) has provided consent to individual disclosure only in respect of part of the Transfers of Value he/she/it received, all Transfers of Value to such HCP or HCO (where applicable) are being disclosed in the aggregate.

Ensuring compliance with Data Privacy Obligations

Almirall certifies that its disclosure complies with the Data Privacy obligations.

27Th June 2019

Peter Guenter

Chief Executive Officer

EFPIA Disclosure Code
2019 Self-Certification Scheme

Healthcare professionals (HCPs) and healthcare organisations (HCOs) with whom Amgen works provide the Pharmaceutical Industry with valuable, independent and expert knowledge derived from their clinical and management experience. As owners of scientific knowledge and experts in medicinal products, pharmaceutical companies can be a unique resource to the healthcare systems and providers, which will ultimately benefit the patients.

Throughout the medicines life cycle pharmaceutical companies work with scientists and HCPs. These collaborations are essential in addressing patient needs. Industry and HCPs collaborate in a range of activities from clinical research to sharing best clinical practice and exchanging information on how new medicines fit into the patient pathway.

EFPIA and its member associations have adopted codes and guidelines to ensure that the interactions of their member companies with HCPs and HCOs meet the high standards of integrity and transparency. Building greater transparency to the relationships between pharmaceutical companies and HCPs/HCOs aims to building understanding of the collaboration and recognition of its value to patient care.

Except in countries where disclosure is prescribed by laws, Amgen hereby confirms that its disclosures of transfers of value (ToVs) to HCPs and HCOs made in 2018 have been reported in application of the EFPIA Disclosure Code following key principles:

Disclosure quality

Amgen certifies that:

- Its disclosures are made in each country where it operates;
- Its disclosures include direct and indirect ToVs, as defined in the codes and associated guidance issued by EFPIA;
- Its Methodological Note describes the process it has followed in order to compile the data hereby disclosed.

Methodology used for the collection and organisation of ToVs is in line with the EFPIA Disclosure Code's requirements and applicable codes

Amgen certifies that:

- Data collection complies with the requirements of the EFPIA Disclosure Code;
- Actions were taken to ensure individual disclosure for HCPs and HCOs' transfers of values (each as defined in the EFPIA Disclosure Code).

Aggregate disclosures are limited to Research and Development ToVs and such ToVs that cannot be disclosed on an individual basis for legal reasons, or where consent is withheld or withdrawn.

Amgen certifies that aggregate disclosure is limited to the following topics:

- Research and Development Transfers of Value (as defined in the EFPIA Disclosure Code);
- Transfers of Value to Recipients that have opposed to the publication on grounds of the protection of their private data;
- If an HCP or HCO (where applicable) has provided consent to individual disclosure only in respect of part of the Transfers of Value he/she/it received, all Transfers of Value to such HCP or HCO (where applicable) are being disclosed in the aggregate.

Ensuring compliance with Data Privacy Obligations

Amgen certifies that its disclosure complies with the Data Privacy obligations.

Date: 24th May 2019

Name of signatory: Tony Hooper

Position in the Company: Executive Vice President

Signature:



astellas

EFPIA Disclosure Code
2019 Self-Certification Scheme

Healthcare professionals (HCPs) and healthcare organisations (HCOs) with whom Astellas Pharma Europe Ltd works provide the Pharmaceutical Industry with valuable, independent and expert knowledge derived from their clinical and management experience. As owners of scientific knowledge and experts in medicinal products, pharmaceutical companies can be a unique resource to the healthcare systems and providers, which will ultimately benefit the patients.

Throughout the medicines life cycle pharmaceutical companies work with scientists and HCPs. These collaborations are essential in addressing patient needs. Industry and HCPs collaborate in a range of activities from clinical research to sharing best clinical practice and exchanging information on how new medicines fit into the patient pathway.

EFPIA and its member associations have adopted codes and guidelines to ensure that the interactions of their member companies with HCPs and HCOs meet the high standards of integrity and transparency. Building greater transparency to the relationships between pharmaceutical companies and HCPs/HCOs aims to building understanding of the collaboration and recognition of its value to patient care.

Except in countries where disclosure is prescribed by laws, Astellas Pharma Europe Ltd hereby confirms that its disclosures of transfers of value (ToVs) to HCPs and HCOs made in 2018 have been reported in application of the EFPIA Disclosure Code following key principles:

Disclosure quality

Astellas Pharma Europe Ltd certifies that:

- Its disclosures are made in each country where it operates;
- Its disclosures include direct and indirect ToVs, as defined in the codes and associated guidance issued by EFPIA;
- Its Methodological Note describes the process it has followed in order to compile the data hereby disclosed.

Methodology used for the collection and organisation of ToVs is in line with the EFPIA Disclosure Code's requirements and applicable codes

Astellas Pharma Europe Ltd.
2000 Hillswood Drive, Chertsey, KT16 0RS. United Kingdom
Tel: +44 (0) 203 379 8000
Registered in England & Wales number 2486792
Registered office as above

Astellas Pharma Europe Ltd certifies that:

- Data collection complies with the requirements of the EFPIA Disclosure Code;
- Actions were taken to ensure individual disclosure for HCPs and HCOs' transfers of values (each as defined in the EFPIA Disclosure Code).

Aggregate disclosures are limited to Research and Development ToVs and such ToVs that cannot be disclosed on an individual basis for legal reasons

Astellas Pharma Europe Ltd certifies that aggregate disclosure is limited to the following topics:

- Research and Development Transfers of Value (as defined in the EFPIA Disclosure Code);
- Transfers of Value to Recipients that have opposed to the publication on grounds of the protection of their private data;
- If an HCP or HCO (where applicable) has provided consent to individual disclosure only in respect of part of the Transfers of Value he/she/it received, all Transfers of Value to such HCP or HCO (where applicable) are being disclosed in the aggregate.

Ensuring compliance with Data Privacy Obligations

Astellas Pharma Europe Ltd certifies that its disclosure complies with the Data Privacy obligations.

Date: July 4, 2019

Name of signatory: **Dr Kenji Yasukawa**

Position in the Company: **President and CEO**

Signature: 

Astellas Pharma Europe Ltd.
2000 Hillswood Drive, Chertsey, KT16 0RS. United Kingdom
Tel: +44 (0) 203 379 8000
Registered in England & Wales number 2486792
Registered office as above

AstraZeneca

EFPIA Disclosure Code
2019 Self-Certification Scheme

Healthcare professionals (HCPs) and Healthcare organisations (HCOs) with whom AstraZeneca works provide the Pharmaceutical Industry with valuable, independent and expert knowledge derived from their clinical and management experience. As owners of scientific knowledge and experts in medicinal products, pharmaceutical companies can be a unique resource to the healthcare systems and providers, which will ultimately benefit the patients.

Throughout the medicines life cycle pharmaceutical companies work with scientists and HCPs. These collaborations are essential in addressing patient needs. Industry and HCPs collaborate in a range of activities from clinical research to sharing best clinical practice and exchanging information on how new medicines fit into the patient pathway.

EFPIA and its member associations have adopted codes and guidelines to ensure that the interactions of their member companies with HCPs and HCOs meet the high standards of integrity and transparency. Building greater transparency to the relationships between pharmaceutical companies and HCPs/HCOs aims to building understanding of the collaboration and recognition of its value to patient care.

Except in countries where disclosure is prescribed by laws, AstraZeneca hereby confirms that its disclosures of transfers of value (ToVs) to HCPs and HCOs made in 2018 have been reported in application of the EFPIA Disclosure Code following key principles:

Disclosure quality

AstraZeneca certifies that:

- Its disclosures are made in each country where it operates;
- Its disclosures include direct and indirect ToVs, as defined in the codes and associated guidance issued by EFPIA;
- Its Methodological Note describes the process it has followed in order to compile the data hereby disclosed.

Methodology used for the collection and organisation of ToVs is in line with the EFPIA Disclosure Code's requirements and applicable codes

AstraZeneca certifies that:

- Data collection complies with the requirements of the EFPIA Disclosure Code;
- Actions were taken to ensure individual disclosure for HCPs and HCOs' transfers of values (each as defined in the EFPIA Disclosure Code).

Aggregate disclosures are limited to Research and Development ToVs and such ToVs that cannot be disclosed on an individual basis for legal reasons

AstraZeneca certifies that aggregate disclosure is limited to the following topics:

- Research and Development Transfers of Value (as defined in the EFPIA Disclosure Code);
- Transfers of Value to Recipients that have opposed to the publication on grounds of the protection of their private data;
- If an HCP or HCO (where applicable) has provided consent to individual disclosure only in respect of part of the Transfers of Value he/she/it received, all Transfers of Value to such HCP or HCO (where applicable) are being disclosed in the aggregate.

Ensuring compliance with Data Privacy Obligations

AstraZeneca certifies that its disclosure complies with the Data Privacy obligations.

Date: 27/6/19

Name of signatory: Iskra Reic 

Position in the Company: Executive Vice President Europe

Signature:

Boehringer Ingelheim

Boehringer Ingelheim GmbH · 55216 Ingelheim am Rhein

EFPIA - European Federation of
Pharmaceutical Industries and Associations
Leopold Plaza Building
Rue du Trône, 108
1050 Bruxelles

June 2019

EFPIA Disclosure Code
2019 Self-Certification Scheme

Healthcare professionals (HCPs) and healthcare organisations (HCOs) with whom Boehringer Ingelheim works provide the Pharmaceutical Industry with valuable, independent and expert knowledge derived from their clinical and management experience. As owners of scientific knowledge and experts in medicinal products, pharmaceutical companies can be a unique resource to the healthcare systems and providers, which will ultimately benefit the patients.

Throughout the medicines life cycle pharmaceutical companies work with scientists and HCPs. These collaborations are essential in addressing patient needs. Industry and HCPs collaborate in a range of activities from clinical research to sharing best clinical practice and exchanging information on how new medicines fit into the patient pathway.

EFPIA and its member associations have adopted codes and guidelines to ensure that the interactions of their member companies with HCPs and HCOs meet the high standards of integrity and transparency. Building greater transparency to the relationships between pharmaceutical companies and HCPs/HCOs aims to building understanding of the collaboration and recognition of its value to patient care.

Except in countries where disclosure is prescribed by laws, Boehringer Ingelheim hereby confirms that its disclosures of transfers of value (ToVs) to HCPs and HCOs made in 2018 have been reported in application of the EFPIA Disclosure Code following key principles:

Disclosure quality

Boehringer Ingelheim certifies that:

- Its disclosures are made in each country where it operates;

Boehringer Ingelheim

- Its disclosures include direct and indirect ToVs, as defined in the codes and associated guidance issued by EFPIA;
- Its Methodological Note describes the process it has followed in order to compile the data hereby disclosed.

Methodology used for the collection and organisation of ToVs is in line with the EFPIA Disclosure Code's requirements and applicable codes

Boehringer Ingelheim certifies that:

- Data collection complies with the requirements of the EFPIA Disclosure Code;
- Actions were taken to ensure individual disclosure for HCPs and HCOs' transfers of values (each as defined in the EFPIA Disclosure Code).

Aggregate disclosures are limited to Research and Development ToVs and such ToVs that cannot be disclosed on an individual basis for legal reasons

Boehringer Ingelheim certifies that aggregate disclosure is limited to the following topics:

- Research and Development Transfers of Value (as defined in the EFPIA Disclosure Code);
- Transfers of Value to Recipients that have opposed to the publication on grounds of the protection of their private data;
- If an HCP or HCO (where applicable) has provided consent to individual disclosure only in respect of part of the Transfers of Value he/she/it received, all Transfers of Value to such HCP or HCO (where applicable) are being disclosed in the aggregate.

Ensuring compliance with Data Privacy Obligations

Boehringer Ingelheim certifies that its disclosure complies with the Data Privacy obligations.

Date: 24/6/19.

Name of signatory: Allan Hillgrove

Position in the Company: Board Member Human Pharma

Signature: 

EFPIA Disclosure Code
2019 Self-Certification Scheme

Healthcare professionals (HCPs) and healthcare organisations (HCOs) with whom BIAL-Portela & Cª, S.A. works provide the Pharmaceutical Industry with valuable, independent and expert knowledge derived from their clinical and management experience. As owners of scientific knowledge and experts in medicinal products, pharmaceutical companies can be a unique resource to the healthcare systems and providers, which will ultimately benefit the patients.

Throughout the medicines life cycle pharmaceutical companies work with scientists and HCPs. These collaborations are essential in addressing patient needs. Industry and HCPs collaborate in a range of activities from clinical research to sharing best clinical practice and exchanging information on how new medicines fit into the patient pathway.

EFPIA and its member associations have adopted codes and guidelines to ensure that the interactions of their member companies with HCPs and HCOs meet the high standards of integrity and transparency. Building greater transparency to the relationships between pharmaceutical companies and HCPs/HCOs aims to building understanding of the collaboration and recognition of its value to patient care.

Except in countries where disclosure is prescribed by laws, BIAL-Portela & Cª, S.A. hereby confirms that its disclosures of transfers of value (ToVs) to HCPs and HCOs made in 2018 have been reported in application of the EFPIA Disclosure Code following key principles:

Disclosure quality

BIAL-Portela & Cª, S.A. certifies that:

- Its disclosures are made in each country where it operates;
- Its disclosures include direct and indirect ToVs, as defined in the codes and associated guidance issued by EFPIA;
- Its Methodological Note describes the process it has followed in order to compile the data hereby disclosed.

Methodology used for the collection and organisation of ToVs is in line with the EFPIA Disclosure Code's requirements and applicable codes

BIAL-Portela & Cª, S.A. certifies that:

- Data collection complies with the requirements of the EFPIA Disclosure Code;
- Actions were taken to ensure individual disclosure for HCPs and HCOs' transfers of values (each as defined in the EFPIA Disclosure Code).

À AV. DA SIDERURGIA NACIONAL • 4745-457 CORONADO (S. Romão e S. Mamede) • PORTUGAL • Tel.: +351 22 986 6100 • Fax: +351 22 986 6190 • www.bial.com • info@bial.com
Sociedade Anónima • Cons. Reg. Com. Trofa Matrícula nº 500 220 913 • NIPC 500 220 913 • Capital Social €50.000.000

Aggregate disclosures are limited to Research and Development ToVs and such ToVs that cannot be disclosed on an individual basis for legal reasons

BIAL-Portela & Cª, S.A. certifies that aggregate disclosure is limited to the following topics:

- Research and Development Transfers of Value (as defined in the EFPIA Disclosure Code);
- Transfers of Value to Recipients that have opposed to the publication on grounds of the protection of their private data;
- If an HCP or HCO (where applicable) has provided consent to individual disclosure only in respect of part of the Transfers of Value he/she/it received, all Transfers of Value to such HCP or HCO (where applicable) are being disclosed in the aggregate.

Ensuring compliance with Data Privacy Obligations

BIAL-Portela & Cª, S.A. certifies that its disclosure complies with the Data Privacy obligations.

Date: 2019.05.22

Name of signatory: António Portela

Position in the Company: Chief Executive Officer

Signature:

EFPIA Disclosure Code
2019 Self-Certification Scheme

Healthcare professionals (HCPs) and healthcare organisations (HCOs) with whom Biogen International GmbH works provide the Pharmaceutical Industry with valuable, independent and expert knowledge derived from their clinical and management experience. As owners of scientific knowledge and experts in medicinal products, pharmaceutical companies can be a unique resource to the healthcare systems and providers, which will ultimately benefit the patients.

Throughout the medicines life cycle pharmaceutical companies work with scientists and HCPs. These collaborations are essential in addressing patient needs. Industry and HCPs collaborate in a range of activities from clinical research to sharing best clinical practice and exchanging information on how new medicines fit into the patient pathway.

EFPIA and its member associations have adopted codes and guidelines to ensure that the interactions of their member companies with HCPs and HCOs meet the high standards of integrity and transparency. Building greater transparency to the relationships between pharmaceutical companies and HCPs/HCOs aims to building understanding of the collaboration and recognition of its value to patient care.

Except in countries where disclosure is prescribed by laws, Biogen International GmbH hereby confirms that its disclosures of transfers of value (ToVs) to HCPs and HCOs made in 2018 have been reported in application of the EFPIA Disclosure Code following key principles:

Disclosure quality

Biogen International GmbH certifies that:

- Its disclosures are made in each country where it operates;
- Its disclosures include direct and indirect ToVs, as defined in the codes and associated guidance issued by EFPIA;
- Its Methodological Note describes the process it has followed in order to compile the data hereby disclosed.

Methodology used for the collection and organisation of ToVs is in line with the EFPIA Disclosure Code's requirements and applicable codes

Biogen International GmbH certifies that:

- Data collection complies with the requirements of the EFPIA Disclosure Code;
- Actions were taken to ensure individual disclosure for HCPs and HCOs' transfers of values (each as defined in the EFPIA Disclosure Code).

Aggregate disclosures are limited to Research and Development ToVs and such ToVs that cannot be disclosed on an individual basis for legal reasons

Biogen International GmbH certifies that aggregate disclosure is limited to the following topics:

- Research and Development Transfers of Value (as defined in the EFPIA Disclosure Code);
- Transfers of Value to Recipients that have opposed to the publication on grounds of the protection of their private data;
- If an HCP or HCO (where applicable) has provided consent to individual disclosure only in respect of part of the Transfers of Value he/she/it received, all Transfers of Value to such HCP or HCO (where applicable) are being disclosed in the aggregate.

Ensuring compliance with Data Privacy Obligations

Biogen International GmbH certifies that its disclosure complies with the Data Privacy obligations.

Date: 23 July 2019

Name of signatory: Pauline Noisel-Krings

Position in the Company: Europe, Canada and Partner Markets Lead Compliance Officer

Signature: 

Bristol-Myers Squibb Company

EFPIA Disclosure Code
2019 Self-Certification Scheme

Healthcare professionals (HCPs) and healthcare organisations (HCOs) with whom Bristol-Myers Squibb Company, LLC works provide the Pharmaceutical Industry with valuable, independent and expert knowledge derived from their clinical and management experience. As owners of scientific knowledge and experts in medicinal products, pharmaceutical companies can be a unique resource to the healthcare systems and providers, which will ultimately benefit the patients.

Throughout the medicines life cycle pharmaceutical companies work with scientists and HCPs. These collaborations are essential in addressing patient needs. Industry and HCPs collaborate in a range of activities from clinical research to sharing best clinical practice and exchanging information on how new medicines fit into the patient pathway.

EFPIA and its member associations have adopted codes and guidelines to ensure that the interactions of their member companies with HCPs and HCOs meet the high standards of integrity and transparency. Building greater transparency to the relationships between pharmaceutical companies and HCPs/HCOs aims to building understanding of the collaboration and recognition of its value to patient care.

Except in countries where disclosure is prescribed by laws, Bristol-Myers Squibb Company, LLC hereby confirms that its disclosures of transfers of value (ToVs) to HCPs and HCOs made in 2018 have been reported in application of the EFPIA Disclosure Code following key principles:

Disclosure quality

Bristol-Myers Squibb Company, LLC certifies that:

- Its disclosures are made in each country where it operates;
- Its disclosures include direct and indirect ToVs, as defined in the codes and associated guidance issued by EFPIA;
- Its Methodological Note describes the process it has followed in order to compile the data hereby disclosed.

Methodology used for the collection and organisation of ToVs is in line with the EFPIA Disclosure Code's requirements and applicable codes

Bristol-Myers Squibb Company, LLC certifies that:

- Data collection complies with the requirements of the EFPIA Disclosure Code;
- Actions were taken to ensure individual disclosure for HCPs and HCOs' transfers of values (each as defined in the EFPIA Disclosure Code).

Aggregate disclosures are limited to Research and Development ToVs and such ToVs that cannot be disclosed on an individual basis for legal reasons

Bristol-Myers Squibb Company, LLC certifies that aggregate disclosure is limited to the following topics:

- Research and Development Transfers of Value (as defined in the EFPIA Disclosure Code);
- Transfers of Value to Recipients that have opposed to the publication on grounds of the protection of their private data;
- If an HCP or HCO (where applicable) has provided consent to individual disclosure only in respect of part of the Transfers of Value he/she/it received, all Transfers of Value to such HCP or HCO (where applicable) are being disclosed in the aggregate.

Ensuring compliance with Data Privacy Obligations

Bristol-Myers Squibb Company, LLC certifies that its disclosure complies with the Data Privacy obligations.

Date:

Name of signatory: Christopher Boerner

Position in the Company: EVP and Chief Commercial Officer

Signature:

EFPIA Disclosure Code
2019 Self-Certification Scheme

Healthcare professionals (HCPs) and healthcare organisations (HCOs) with whom Celgene Corporation works provide the Pharmaceutical Industry with valuable, independent and expert knowledge derived from their clinical and management experience. As owners of scientific knowledge and experts in medicinal products, pharmaceutical companies can be a unique resource to the healthcare systems and providers, which will ultimately benefit the patients.

Throughout the medicines life cycle pharmaceutical companies work with scientists and HCPs. These collaborations are essential in addressing patient needs. Industry and HCPs collaborate in a range of activities from clinical research to sharing best clinical practice and exchanging information on how new medicines fit into the patient pathway.

EFPIA and its member associations have adopted codes and guidelines to ensure that the interactions of their member companies with HCPs and HCOs meet the high standards of integrity and transparency. Building greater transparency to the relationships between pharmaceutical companies and HCPs/HCOs aims to building understanding of the collaboration and recognition of its value to patient care.

Except in countries where disclosure is prescribed by laws, Celgene Corporation hereby confirms that its disclosures of transfers of value (ToVs) to HCPs and HCOs made in 2018 have been reported in application of the EFPIA Disclosure Code following key principles:

Disclosure quality

Celgene Corporation certifies that:

- Its disclosures are made in each country where it operates;
- Its disclosures include direct and indirect ToVs, as defined in the codes and associated guidance issued by EFPIA;
- Its Methodological Note describes the process it has followed in order to compile the data hereby disclosed.

Methodology used for the collection and organisation of ToVs is in line with the EFPIA Disclosure Code's requirements and applicable codes

Celgene Corporation certifies that:

- Data collection complies with the requirements of the EFPIA Disclosure Code;
- Actions were taken to ensure individual disclosure for HCPs and HCOs' transfers of values (each as defined in the EFPIA Disclosure Code).

Aggregate disclosures are limited to Research and Development ToVs and such ToVs that cannot be disclosed on an individual basis for legal reasons

Celgene Corporation certifies that aggregate disclosure is limited to the following topics:

- Research and Development Transfers of Value (as defined in the EFPIA Disclosure Code);
- Transfers of Value to Recipients that have opposed to the publication on grounds of the protection of their private data;
- If an HCP or HCO (where applicable) has provided consent to individual disclosure only in respect of part of the Transfers of Value he/she/it received, all Transfers of Value to such HCP or HCO (where applicable) are being disclosed in the aggregate.

Ensuring compliance with Data Privacy Obligations

Celgene Corporation certifies that its disclosure complies with the Data Privacy obligations.

Name of signatory: Nadim Ahmed

Position in the Company: President, Hematology and Oncology

Date:

Signature: 6/19/19



CHIESI FARMACEUTICI S.p.A.
Via Palermo 26/A
43122, Parma (PR)
Tel.: +39 0521 2791
Fax: +39 0521 774468
info@chiesi.com
Info@pec.chiesi.com

People and ideas for innovation in healthcare

EFPIA Disclosure Code
2019 Self-Certification Scheme

Healthcare professionals (HCPs) and healthcare organisations (HCOs) with whom Chiesi Farmaceutici S.p.A. works provide the Pharmaceutical Industry with valuable, independent and expert knowledge derived from their clinical and management experience. As owners of scientific knowledge and experts in medicinal products, pharmaceutical companies can be a unique resource to the healthcare systems and providers, which will ultimately benefit the patients.

Throughout the medicines life cycle pharmaceutical companies work with scientists and HCPs. These collaborations are essential in addressing patient needs. Industry and HCPs collaborate in a range of activities from clinical research to sharing best clinical practice and exchanging information on how new medicines fit into the patient pathway.

EFPIA and its member associations have adopted codes and guidelines to ensure that the interactions of their member companies with HCPs and HCOs meet the high standards of integrity and transparency. Building greater transparency to the relationships between pharmaceutical companies and HCPs/HCOs aims to building understanding of the collaboration and recognition of its value to patient care.

Except in countries where disclosure is prescribed by laws, Chiesi Farmaceutici S.p.A. hereby confirms that its disclosures of transfers of value (ToVs) to HCPs and HCOs made in 2018 have been reported in application of the EFPIA Disclosure Code following key principles:

Disclosure quality

Chiesi Farmaceutici S.p.A. certifies that:

- Its disclosures are made in each country where it operates;
- Its disclosures include direct and indirect ToVs, as defined in the codes and associated guidance issued by EFPIA;
- Its Methodological Note describes the process it has followed in order to compile the data hereby disclosed.

Methodology used for the collection and organisation of ToVs is in line with the EFPIA Disclosure Code's requirements and applicable codes

Chiesi Farmaceutici S.p.A. certifies that:

- Data collection complies with the requirements of the EFPIA Disclosure Code;
- Actions were taken to ensure individual disclosure for HCPs and HCOs' transfers of values (each as defined in the EFPIA Disclosure Code).

CHIESI FARMACEUTICI S.p.A.
Via Palermo 26/A
43122, Parma (PR)
Tel.: +39 0521 2791
Fax: +39 0521 774468
info@chiesi.com
Info@pec.chiesi.com

Aggregate disclosures are limited to Research and Development ToVs and such ToVs that cannot be disclosed on an individual basis for legal reasons

Chiesi Farmaceutici S.p.A. certifies that aggregate disclosure is limited to the following topics:

- Research and Development Transfers of Value (as defined in the EFPIA Disclosure Code);
- Transfers of Value to Recipients that have opposed to the publication on grounds of the protection of their private data;
- If an HCP or HCO (where applicable) has provided consent to individual disclosure only in respect of part of the Transfers of Value he/she/it received, all Transfers of Value to such HCP or HCO (where applicable) are being disclosed in the aggregate.

Ensuring compliance with Data Privacy Obligations

Chiesi Farmaceutici S.p.A. certifies that its disclosure complies with the Data Privacy obligations.

Date:	June 26th, 2019
Name of signatory:	Alberto Chiesi
Position in the Company:	President
Signature:	

Torre Esteve
Pg. de la Zona Franca, 109, 4ª planta
08038 Barcelona (Spain)

Tel. +34 93 446 60 00
www.esteve.com

EFPIA Disclosure Code
2019 Self-Certification Scheme

Healthcare professionals (HCPs) and healthcare organisations (HCOs) with whom Esteve Pharmaceuticals, S.A. works provide the Pharmaceutical Industry with valuable, independent and expert knowledge derived from their clinical and management experience. As owners of scientific knowledge and experts in medicinal products, pharmaceutical companies can be a unique resource to the healthcare systems and providers, which will ultimately benefit the patients.

Throughout the medicines life cycle pharmaceutical companies work with scientists and HCPs. These collaborations are essential in addressing patient needs. Industry and HCPs collaborate in a range of activities from clinical research to sharing best clinical practice and exchanging information on how new medicines fit into the patient pathway.

EFPIA and its member associations have adopted codes and guidelines to ensure that the interactions of their member companies with HCPs and HCOs meet the high standards of integrity and transparency. Building greater transparency to the relationships between pharmaceutical companies and HCPs/HCOs aims to building understanding of the collaboration and recognition of its value to patient care.

Except in countries where disclosure is prescribed by laws, Esteve Pharmaceuticals, S.A. hereby confirms that its disclosures of transfers of value (ToVs) to HCPs and HCOs made in 2018 have been reported in application of the EFPIA Disclosure Code following key principles:

Disclosure quality

Esteve Pharmaceuticals, S.A. certifies that:

- Its disclosures are made in each country where it operates;
- Its disclosures include direct and indirect ToVs, as defined in the codes and associated guidance issued by EFPIA;
- Its Methodological Note describes the process it has followed in order to compile the data hereby disclosed.

Methodology used for the collection and organisation of ToVs is in line with the EFPIA Disclosure Code's requirements and applicable codes

Esteve Pharmaceuticals, S.A. certifies that:

- Data collection complies with the requirements of the EFPIA Disclosure Code;
- Actions were taken to ensure individual disclosure for HCPs and HCOs' transfers of values (each as defined in the EFPIA Disclosure Code).

Esteve Pharmaceuticals, S.A. Sociedad Unipersonal
Inscrita R.M. Barcelona
Hoja B-19.337, Folio 148, Tomo 312, Inscripción 1a
N.I.F. A 08037236

Torre Esteve
Pg. de la Zona Franca, 109, 4ª planta
08038 Barcelona (Spain)

Tel. +34 93 446 60 00
www.esteve.com

Aggregate disclosures are limited to Research and Development ToVs and such ToVs that cannot be disclosed on an individual basis for legal reasons

Esteve Pharmaceuticals, S.A. certifies that aggregate disclosure is limited to the following topics:

- Research and Development Transfers of Value (as defined in the EFPIA Disclosure Code);
- Transfers of Value to Recipients that have opposed to the publication on grounds of the protection of their private data;
- If an HCP or HCO (where applicable) has provided consent to individual disclosure only in respect of part of the Transfers of Value he/she/it received, all Transfers of Value to such HCP or HCO (where applicable) are being disclosed in the aggregate.

Ensuring compliance with Data Privacy Obligations

Esteve Pharmaceuticals, S.A. certifies that its disclosure complies with the Data Privacy obligations.

7/06/2019

Staffan Schüberg
Chief Executive Officer

Signature:

Esteve Pharmaceuticals, S.A. Sociedad Unipersonal
Inscrita R.M. Barcelona
Hoja B-19.337, Folio 148, Tomo 312, Inscripción 1a
N.I.F. A 08037236

GlaxoSmithKline Services Unlimited
980 Great West Road
Brentford
Middlesex
TW8 9GS

T +44 2080 475 000
www.gsk.com

EFPIA Disclosure Code
2019 Self-Certification Scheme

Healthcare professionals (HCPs) and healthcare organisations (HCOs) with whom GlaxoSmithKline works provide the Pharmaceutical Industry with valuable, independent and expert knowledge derived from their clinical and management experience. As owners of scientific knowledge and experts in medicinal products, pharmaceutical companies can be a unique resource to the healthcare systems and providers, which will ultimately benefit the patients.

Throughout the medicines life cycle pharmaceutical companies work with scientists and HCPs. These collaborations are essential in addressing patient needs. Industry and HCPs collaborate in a range of activities from clinical research to sharing best clinical practice and exchanging information on how new medicines fit into the patient pathway.

EFPIA and its member associations have adopted codes and guidelines to ensure that the interactions of their member companies with HCPs and HCOs meet the high standards of integrity and transparency. Building greater transparency to the relationships between pharmaceutical companies and HCPs/HCOs aims to building understanding of the collaboration and recognition of its value to patient care.

Except in countries where disclosure is prescribed by laws, GlaxoSmithKline hereby confirms that its disclosures of transfers of value (ToVs) to HCPs and HCOs made in 2018 have been reported in application of the EFPIA Disclosure Code following key principles:

Disclosure quality

GlaxoSmithKline certifies that:

- Its disclosures are made in each country where it operates;
- Its disclosures include direct and indirect ToVs, as defined in the codes and associated guidance issued by EFPIA;
- Its Methodological Note describes the process it has followed in order to compile the data hereby disclosed.

Methodology used for the collection and organisation of ToVs is in line with the EFPIA Disclosure Code's requirements and applicable codes

GlaxoSmithKline certifies that:

- Data collection complies with the requirements of the EFPIA Disclosure Code;
- Actions were taken to ensure individual disclosure for HCPs and HCOs' transfers of values (each as defined in the EFPIA Disclosure Code).

Registered in England and Wales
No. 1047315

Registered Office
980 Great West Road, Brentford
Middlesex, TW8 9GS

Aggregate disclosures are limited to Research and Development ToVs and such ToVs that cannot be disclosed on an individual basis for legal reasons

GlaxoSmithKline certifies that aggregate disclosure is limited to the following topics:

- Research and Development Transfers of Value (as defined in the EFPIA Disclosure Code);
- Transfers of Value to Recipients that have opposed to the publication on grounds of the protection of their private data;
- If an HCP or HCO (where applicable) has provided consent to individual disclosure only in respect of part of the Transfers of Value he/she/it received, all Transfers of Value to such HCP or HCO (where applicable) are being disclosed in the aggregate.

Ensuring compliance with Data Privacy Obligations

GlaxoSmithKline certifies that its disclosure complies with the Data Privacy obligations.

Date: 10 June 2019

Name of signatory: Luke Miels

Position in the Company: President Global Pharmaceuticals

Signature: 

EFPIA Disclosure Code
2019 Self-Certification Scheme

Healthcare professionals (HCPs) and healthcare organisations (HCOs) with whom Ipsen works provide the Pharmaceutical Industry with valuable, independent and expert knowledge derived from their clinical and management experience. As owners of scientific knowledge and experts in medicinal products, pharmaceutical companies can be a unique resource to the healthcare systems and providers, which will ultimately benefit the patients.

Throughout the medicines life cycle pharmaceutical companies work with scientists and HCPs. These collaborations are essential in addressing patient needs. Industry and HCPs collaborate in a range of activities from clinical research to sharing best clinical practice and exchanging information on how new medicines fit into the patient pathway.

EFPIA and its member associations have adopted codes and guidelines to ensure that the interactions of their member companies with HCPs and HCOs meet the high standards of integrity and transparency. Building greater transparency to the relationships between pharmaceutical companies and HCPs/HCOs aims to building understanding of the collaboration and recognition of its value to patient care.

Except in countries where disclosure is prescribed by laws, Ipsen hereby confirms that its disclosures of transfers of value (ToVs) to HCPs and HCOs made in 2018 have been reported in application of the EFPIA Disclosure Code following key principles:

Disclosure quality

Ipsen certifies that:

- Its disclosures are made in each country where it operates;
- Its disclosures include direct and indirect ToVs, as defined in the codes and associated guidance issued by EFPIA;
- Its Methodological Note describes the process it has followed in order to compile the data hereby disclosed.

Methodology used for the collection and organisation of ToVs is in line with the EFPIA Disclosure Code's requirements and applicable codes

Ipsen certifies that:

- Data collection complies with the requirements of the EFPIA Disclosure Code;
- Actions were taken to ensure individual disclosure for HCPs and HCOs' transfers of values (each as defined in the EFPIA Disclosure Code).

Aggregate disclosures are limited to Research and Development ToVs and such ToVs that cannot be disclosed on an individual basis for legal reasons

Ipsen certifies that aggregate disclosure is limited to the following topics:

- Research and Development Transfers of Value (as defined in the EFPIA Disclosure Code);
- Transfers of Value to Recipients that have opposed to the publication on grounds of the protection of their private data;
- If an HCP or HCO (where applicable) has provided consent to individual disclosure only in respect of part of the Transfers of Value he/she/it received, all Transfers of Value to such HCP or HCO (where applicable) are being disclosed in the aggregate.

Ensuring compliance with Data Privacy Obligations

Ipsen certifies that its disclosure complies with the Data Privacy obligations.

Date: 28th of June 2019

Name of signatory: David Meek

Position in the Company: Chief Executive Officer

Signature:

Janssen Pharmaceutica NV
Turnhoutseweg 30
B-2340 Beerse, Belgium

EFPIA Disclosure Code
2019 Self-Certification Scheme

Healthcare professionals (HCPs) and healthcare organisations (HCOs) with whom Janssen, Pharmaceutical Companies of J&J, works provide the Pharmaceutical Industry with valuable, independent and expert knowledge derived from their clinical and management experience. As owners of scientific knowledge and experts in medicinal products, pharmaceutical companies can be a unique resource to the healthcare systems and providers, which will ultimately benefit the patients.

Throughout the medicines life cycle pharmaceutical companies work with scientists and HCPs. These collaborations are essential in addressing patient needs. Industry and HCPs collaborate in a range of activities from clinical research to sharing best clinical practice and exchanging information on how new medicines fit into the patient pathway.

EFPIA and its member associations have adopted codes and guidelines to ensure that the interactions of their member companies with HCPs and HCOs meet the high standards of integrity and transparency. Building greater transparency to the relationships between pharmaceutical companies and HCPs/HCOs aims to building understanding of the collaboration and recognition of its value to patient care.

Except in countries where disclosure is prescribed by laws, Janssen hereby confirms that its disclosures of transfers of value (ToVs) to HCPs and HCOs made in 2018 have been reported in application of the EFPIA Disclosure Code following key principles:

Disclosure quality

Janssen certifies that:

- Its disclosures are made in each country where it operates;
- Its disclosures include direct and indirect ToVs, as defined in the codes and associated guidance issued by EFPIA;
- Its Methodological Note describes the process it has followed in order to compile the data hereby disclosed.

Methodology used for the collection and organisation of ToVs is in line with the EFPIA Disclosure Code's requirements and applicable codes

Janssen certifies that:

- Data collection complies with the requirements of the EFPIA Disclosure Code;
- Actions were taken to ensure individual disclosure for HCPs and HCOs' transfers of values (each as defined in the EFPIA Disclosure Code).

Aggregate disclosures are limited to Research and Development ToVs and such ToVs that cannot be disclosed on an individual basis for legal reasons

Janssen certifies that aggregate disclosure is limited to the following topics:

- Research and Development Transfers of Value (as defined in the EFPIA Disclosure Code);
- Transfers of Value to Recipients that have opposed to the publication on grounds of the protection of their private data;
- If an HCP or HCO (where applicable) has provided consent to individual disclosure only in respect of part of the Transfers of Value he/she/it received, all Transfers of Value to such HCP or HCO (where applicable) are being disclosed in the aggregate.

Ensuring compliance with Data Privacy Obligations

Janssen certifies that its disclosure complies with the Data Privacy obligations.

Date: 17 June 2019

Name of signatory: Kris Sterkens

Position in the Company: Company Group Chairman Janssen EMEA

Signature:

Dermatology
beyond the skin

LEO Pharma A/S
Industriparken 55
2750 Ballerup
Denmark

Main +45 4494 5888
Fax +45 7226 3321

www.leo-pharma.com
CVR no.: 56 75 95 14

EFPIA Disclosure Code
2019 Self-Certification Scheme

Healthcare professionals (HCPs) and healthcare organisations (HCOs) with whom LEO Pharma works provide the Pharmaceutical Industry with valuable, independent and expert knowledge derived from their clinical and management experience. As owners of scientific knowledge and experts in medicinal products, pharmaceutical companies can be a unique resource to the healthcare systems and providers, which will ultimately benefit the patients.

Throughout the medicines life cycle pharmaceutical companies work with scientists and HCPs. These collaborations are essential in addressing patient needs. Industry and HCPs collaborate in a range of activities from clinical research to sharing best clinical practice and exchanging information on how new medicines fit into the patient pathway.

EFPIA and its member associations have adopted codes and guidelines to ensure that the interactions of their member companies with HCPs and HCOs meet the high standards of integrity and transparency. Building greater transparency to the relationships between pharmaceutical companies and HCPs/HCOs aims to building understanding of the collaboration and recognition of its value to patient care.

Except in countries where disclosure is prescribed by laws, LEO Pharma hereby confirms that its disclosures of transfers of value (ToVs) to HCPs and HCOs made in 2018 have been reported in application of the EFPIA Disclosure Code following key principles:

Disclosure quality

LEO Pharma certifies that:

- Its disclosures are made in each country where it operates;
- Its disclosures include direct and indirect ToVs, as defined in the codes and associated guidance issued by EFPIA;
- Its Methodological Note describes the process it has followed in order to compile the data hereby disclosed.

Methodology used for the collection and organisation of ToVs is in line with the EFPIA Disclosure Code's requirements and applicable codes

LEO Pharma certifies that:

- Data collection complies with the requirements of the EFPIA Disclosure Code;
- Actions were taken to ensure individual disclosure for HCPs and HCOs' transfers of values (each as defined in the EFPIA Disclosure Code).

Aggregate disclosures are limited to Research and Development ToVs and such ToVs that cannot be disclosed on an individual basis for legal reasons

LEO Pharma certifies that aggregate disclosure is limited to the following topics:

- Research and Development Transfers of Value (as defined in the EFPIA Disclosure Code);
- Transfers of Value to Recipients that have opposed to the publication on grounds of the protection of their private data;
- If an HCP or HCO (where applicable) has provided consent to individual disclosure only in respect of part of the Transfers of Value he/she/it received, all Transfers of Value to such HCP or HCO (where applicable) are being disclosed in the aggregate.

Ensuring compliance with Data Privacy Obligations

LEO Pharma certifies that its disclosure complies with the Data Privacy obligations.

Date: 24.06.2019

Name of signatory: **Gitte P. Aabo**

Position in the Company: **President & CEO**

Signature:

Eli Lilly and Company
Lilly Corporate Center
Indianapolis, Indiana 46285
U.S.A
+1 317 276 2000
www.lilly.com

EFPIA Disclosure Code
2019 Self-Certification Scheme

Healthcare professionals (HCPs) and healthcare organisations (HCOs) with whom Eli Lilly and Company (Lilly) works provide the Pharmaceutical Industry with valuable, independent and expert knowledge derived from their clinical and management experience. As owners of scientific knowledge and experts in medicinal products, pharmaceutical companies can be a unique resource to the healthcare systems and providers, which will ultimately benefit the patients.

Throughout the medicines life cycle pharmaceutical companies work with scientists and HCPs. These collaborations are essential in addressing patient needs. Industry and HCPs collaborate in a range of activities from clinical research to sharing best clinical practice and exchanging information on how new medicines fit into the patient pathway.

EFPIA and its member associations have adopted codes and guidelines to ensure that the interactions of their member companies with HCPs and HCOs meet the high standards of integrity and transparency. Building greater transparency to the relationships between pharmaceutical companies and HCPs/HCOs aims to building understanding of the collaboration and recognition of its value to patient care.

Except in countries where disclosure is prescribed by laws, Lilly hereby confirms that its disclosures of transfers of value (ToVs) to HCPs and HCOs made in 2018 have been reported in application of the EFPIA Disclosure Code following key principles:

Disclosure quality

Lilly certifies that:

- Its disclosures are made in each country where it operates;
- Its disclosures include direct and indirect ToVs, as defined in the codes and associated guidance issued by EFPIA;
- Its Methodological Note describes the process it has followed in order to compile the data hereby disclosed.

Methodology used for the collection and organisation of ToVs is in line with the EFPIA Disclosure Code's requirements and applicable codes

Lilly certifies that:

- Data collection complies with the requirements of the EFPIA Disclosure Code;
- Actions were taken to ensure individual disclosure for HCPs and HCOs' transfers of values (each as defined in the EFPIA Disclosure Code).

Aggregate disclosures are limited to Research and Development ToVs and such ToVs that cannot be disclosed on an individual basis for legal reasons

Lilly certifies that aggregate disclosure is limited to the following topics:

- Research and Development Transfers of Value (as defined in the EFPIA Disclosure Code);
- Transfers of Value to Recipients that have opposed to the publication on grounds of the protection of their private data;
- If an HCP or HCO (where applicable) has provided consent to individual disclosure only in respect of part of the Transfers of Value he/she/it received, all Transfers of Value to such HCP or HCO (where applicable) are being disclosed in the aggregate.

Ensuring compliance with Data Privacy Obligations

Lilly certifies that its disclosure complies with the Data Privacy obligations.

X

Alfonso G. Zulueta

Senior Vice-President and President of Lilly International

May 2019

EFPIA Disclosure Code
2019 Self-Certification Scheme

Healthcare professionals (HCPs) and healthcare organisations (HCOs) with whom H. Lundbeck A/S ("Lundbeck") works provide the Pharmaceutical Industry with valuable, independent and expert knowledge derived from their clinical and management experience. As owners of scientific knowledge and experts in medicinal products, pharmaceutical companies can be a unique resource to the healthcare systems and providers, which will ultimately benefit the patients.

Throughout the medicines life cycle pharmaceutical companies work with scientists and HCPs. These collaborations are essential in addressing patient needs. Industry and HCPs collaborate in a range of activities from clinical research to sharing best clinical practice and exchanging information on how new medicines fit into the patient pathway.

EFPIA and its member associations have adopted codes and guidelines to ensure that the interactions of their member companies with HCPs and HCOs meet the high standards of integrity and transparency. Building greater transparency to the relationships between pharmaceutical companies and HCPs/HCOs aims to building understanding of the collaboration and recognition of its value to patient care.

Except in countries where disclosure is prescribed by laws, Lundbeck hereby confirms that its disclosures of transfers of value (ToVs) to HCPs and HCOs made in 2018 have been reported in application of the EFPIA Disclosure Code following key principles:

Disclosure quality

Lundbeck certifies that:

- Its disclosures are made in each country where it operates;
- Its disclosures include direct and indirect ToVs, as defined in the codes and associated guidance issued by EFPIA;
- Its Methodological Note describes the process it has followed in order to compile the data hereby disclosed.

Methodology used for the collection and organisation of ToVs is in line with the EFPIA Disclosure Code's requirements and applicable codes

Lundbeck certifies that:

- Data collection complies with the requirements of the EFPIA Disclosure Code;
- Actions were taken to ensure individual disclosure for HCPs and HCOs' transfers of values (each as defined in the EFPIA Disclosure Code).

Aggregate disclosures are limited to Research and Development ToVs and such ToVs that cannot be disclosed on an individual basis for legal reasons

Lundbeck certifies that aggregate disclosure is limited to the following topics:

- Research and Development Transfers of Value (as defined in the EFPIA Disclosure Code);
- Transfers of Value to Recipients that have opposed to the publication on grounds of the protection of their private data;
- If an HCP or HCO (where applicable) has provided consent to individual disclosure only in respect of part of the Transfers of Value he/she/it received, all Transfers of Value to such HCP or HCO (where applicable) are being disclosed in the aggregate.

Ensuring compliance with Data Privacy Obligations

Lundbeck certifies that its disclosure complies with the Data Privacy obligations.

Deborah Dunsire
CEO, H. Lundbeck A/S

Date: 27.05.19

A. MENARINI
INDUSTRIE FARMACEUTICHE RIUNITE

EFPIA Disclosure Code
2019 Self-Certification Scheme

Healthcare professionals (HCPs) and healthcare organisations (HCOs) with whom A. Menarini Industrie Farmaceutiche Riunite S.r.l. works provide the Pharmaceutical Industry with valuable, independent and expert knowledge derived from their clinical and management experience. As owners of scientific knowledge and experts in medicinal products, pharmaceutical companies can be a unique resource to the healthcare systems and providers, which will ultimately benefit the patients.

Throughout the medicines life cycle pharmaceutical companies work with scientists and HCPs. These collaborations are essential in addressing patient needs. Industry and HCPs collaborate in a range of activities from clinical research to sharing best clinical practice and exchanging information on how new medicines fit into the patient pathway.

EFPIA and its member associations have adopted codes and guidelines to ensure that the interactions of their member companies with HCPs and HCOs meet the high standards of integrity and transparency. Building greater transparency to the relationships between pharmaceutical companies and HCPs/HCOs aims to building understanding of the collaboration and recognition of its value to patient care.

Except in countries where disclosure is prescribed by laws, A. Menarini Industrie Farmaceutiche Riunite S.r.l. hereby confirms that its disclosures of transfers of value (ToVs) to HCPs and HCOs made in 2018 have been reported in application of the EFPIA Disclosure Code following key principles:

Disclosure quality

A. Menarini Industrie Farmaceutiche Riunite S.r.l. certifies that:

- Its disclosures are made in each country where it operates;
- Its disclosures include direct and indirect ToVs, as defined in the codes and associated guidance issued by EFPIA;
- Its Methodological Note describes the process it has followed in order to compile the data hereby disclosed.

Methodology used for the collection and organisation of ToVs is in line with the EFPIA Disclosure Code's requirements and applicable codes

A. MENARINI
INDUSTRIE FARMACEUTICHE RIUNITE

A. Menarini Industrie Farmaceutiche Riunite S.r.l. certifies that:

- Data collection complies with the requirements of the EFPIA Disclosure Code,
- Actions were taken to ensure individual disclosure for HCPs and HCOs' transfers of values (each as defined in the EFPIA Disclosure Code)

Aggregate disclosures are limited to Research and Development ToVs and such ToVs that cannot be disclosed on an individual basis for legal reasons

A. Menarini Industrie Farmaceutiche Riunite S.r.l. certifies that aggregate disclosure is limited to the following topics

- Research and Development Transfers of Value (as defined in the EFPIA Disclosure Code);
- Transfers of Value to Recipients that have opposed to the publication on grounds of the protection of their private data;
- If an HCP or HCO (where applicable) has provided consent to individual disclosure only in respect of part of the Transfers of Value he/she/it received, all Transfers of Value to such HCP or HCO (where applicable) are being disclosed in the aggregate

Ensuring compliance with Data Privacy Obligations

A. Menarini Industrie Farmaceutiche Riunite S.r.l certifies that its disclosure complies with the Data Privacy obligations.

Date:	24 June 2019
Name of signatory:	Eric Cornut
Position in the Company:	Chairman of the Board of Directors
Signature	

EFPIA Disclosure Code
2019 Self-Certification Scheme

Healthcare professionals (HCPs) and healthcare organisations (HCOs) with whom Merck works provide the Pharmaceutical Industry with valuable, independent and expert knowledge derived from their clinical and management experience. As owners of scientific knowledge and experts in medicinal products, pharmaceutical companies can be a unique resource to the healthcare systems and providers, which will ultimately benefit the patients.

Throughout the medicines life cycle pharmaceutical companies work with scientists and HCPs. These collaborations are essential in addressing patient needs. Industry and HCPs collaborate in a range of activities from clinical research to sharing best clinical practice and exchanging information on how new medicines fit into the patient pathway.

EFPIA and its member associations have adopted codes and guidelines to ensure that the interactions of their member companies with HCPs and HCOs meet the high standards of integrity and transparency. Building greater transparency to the relationships between pharmaceutical companies and HCPs/HCOs aims to building understanding of the collaboration and recognition of its value to patient care.

Except in countries where disclosure is prescribed by laws, Merck hereby confirms that its disclosures of transfers of value (ToVs) to HCPs and HCOs made in 2018 have been reported in application of the EFPIA Disclosure Code following key principles:

Disclosure quality

Merck certifies that:

- Its disclosures are made in each country where it operates;
- Its disclosures include direct and indirect ToVs, as defined in the codes and associated guidance issued by EFPIA;
- Its Methodological Note describes the process it has followed in order to compile the data hereby disclosed.

Methodology used for the collection and organisation of ToVs is in line with the EFPIA Disclosure Code's requirements and applicable codes

Merck certifies that:

- Data collection complies with the requirements of the EFPIA Disclosure Code;
- Actions were taken to ensure individual disclosure for HCPs and HCOs' transfers of values (each as defined in the EFPIA Disclosure Code).

Aggregate disclosures are limited to Research and Development ToVs and such ToVs that cannot be disclosed on an individual basis for legal reasons

Merck certifies that aggregate disclosure is limited to the following topics:

- Research and Development Transfers of Value (as defined in the EFPIA Disclosure Code);
- Transfers of Value to Recipients that have opposed to the publication on grounds of the protection of their private data;
- If an HCP or HCO (where applicable) has provided consent to individual disclosure only in respect of part of the Transfers of Value he/she/it received, all Transfers of Value to such HCP or HCO (where applicable) are being disclosed in the aggregate.

Ensuring compliance with Data Privacy Obligations

Merck certifies that its disclosure complies with the Data Privacy obligations.

Date: 13 June 2019

Name of signatory: Stefan Oschmann

Position in the Company: Chairman of the Executive Board & CEO

Signature: 

Frank K. Clyburn

Chief Commercial Officer
Merck & Co., Inc.

Merck & Co., Inc.
2000 Galloping Hill Road
Kenilworth, NJ 07033 M
U.S.A
Phone: 1.908-740-4000
merck.com

EFPIA Disclosure Code
2019 Self-Certification Scheme

Healthcare professionals (HCPs) and healthcare organisations (HCOs) with whom Merck & Co., Inc. works provide the Pharmaceutical Industry with valuable, independent and expert knowledge derived from their clinical and management experience. As owners of scientific knowledge and experts in medicinal products, pharmaceutical companies can be a unique resource to the healthcare systems and providers, which will ultimately benefit the patients.

Throughout the medicines life cycle pharmaceutical companies work with scientists and HCP's. These collaborations are essential in addressing patient needs. Industry and healthcare professionals collaborate in a range of activities from clinical research to sharing best clinical practice and exchanging information on how new medicines fit into the patient pathway.

EFPIA and its member associations have adopted codes and guidelines to ensure that the interactions of their member companies with HCP's and HCO's meet the high standards of integrity and transparency. Building greater transparency to the relationships between pharma companies and HCPs/HCOs aims to building understanding of the collaboration and recognition of its value to patient care.

Except in countries where disclosure is prescribed by law, Merck & Co., Inc. hereby confirms that its disclosures of transfers of value (ToVs) to HCPs and HCOs made in 2018 have been reported in application of the EFPIA Disclosure Code following key principles:

Disclosure quality

Merck & Co., Inc. certifies that:

- Its disclosures are made in each country where it operates;
- Its disclosures include direct and indirect ToVs, as defined in the codes and associated guidance issued by EFPIA;
- Its Methodological Note describes the process it has followed in order to compile the data hereby disclosed.

Frank K. Clyburn

Chief Commercial Officer
Merck & Co., Inc.

Merck & Co., Inc.
2000 Galloping Hill Road
Kenilworth, NJ 07033 M
U.S.A
Phone: 1.908-740-4000
merck.com

Methodology used for the collection and organisation of ToVs is in line with the EFPIA Disclosure Code's requirements and applicable codes

Merck & Co., Inc. certifies that:

- Data collection complies with the requirements of the EFPIA Disclosure Code;
- Actions were taken to ensure individual disclosure for HCPs and HCOs transfer of value (each as defined in the EFPIA Disclosure Code).

Aggregate disclosures are limited to Research and Development ToVs and such ToVs that cannot be disclosed on an individual basis for legal reasons

Merck & Co., Inc. certifies that aggregate disclosure is limited to the following topics:

- Research and Development Transfers of Value (as defined in the EFPIA Disclosure Code);
- Transfers of Value to Recipients that have opposed to the publication on grounds of the protection of their private data;
- If an HCP or HCO (where applicable) has provided consent to individual disclosure only in respect of part of the Transfers of Value he/she/it received, all Transfers of Value to such HCP or HCO (where applicable) are being disclosed in the aggregate.

Ensuring compliance with Data Privacy Obligations

Merck & Co., Inc. certifies that its disclosure complies with the Data Privacy obligations.

Date: June 3, 2019

Name of signatory: Frank K. Clyburn

Position in the Company: Chief Commercial Officer, Merck & Co., Inc.

Signature:

Novartis Pharma AG
Communication
Novartis Campus
Postfach
4002 Basel
Switzerland
T: +41 61 324 1321

EFPIA Disclosure Code - 2019 Self-Certification Scheme

Healthcare professionals (HCPs) and healthcare organisations (HCOs) with whom Novartis Pharma AG works provide the Pharmaceutical Industry with valuable, independent and expert knowledge derived from their clinical and management experience. As owners of scientific knowledge and experts in medicinal products, pharmaceutical companies can be a unique resource to the healthcare systems and providers, which will ultimately benefit the patients.

Throughout the medicines life cycle pharmaceutical companies work with scientists and HCPs. These collaborations are essential in addressing patient needs. Industry and HCPs collaborate in a range of activities from clinical research to sharing best clinical practice and exchanging information on how new medicines fit into the patient pathway.

EFPIA and its member associations have adopted codes and guidelines to ensure that the interactions of their member companies with HCPs and HCOs meet the high standards of integrity and transparency. Building greater transparency to the relationships between pharmaceutical companies and HCPs/HCOs aims to building understanding of the collaboration and recognition of its value to patient care.

Except in countries where disclosure is prescribed by laws, Novartis Pharma AG hereby confirms that its disclosures of transfers of value (ToVs) to HCPs and HCOs made in 2018 have been reported in application of the EFPIA Disclosure Code following key principles:

Disclosure quality

Novartis Pharma AG certifies that:

- Its disclosures are made in each country where it operates;
- Its disclosures include direct and indirect ToVs, as defined in the codes and associated guidance issued by EFPIA;
- Its Methodological Note describes the process it has followed in order to compile the data hereby disclosed.

Methodology used for the collection and organisation of ToVs is in line with the EFPIA Disclosure Code's requirements and applicable codes

Novartis Pharma AG certifies that:

- Data collection complies with the requirements of the EFPIA Disclosure Code;
- Actions were taken to ensure individual disclosure for HCPs' and HCOs' transfers of values (each as defined in the EFPIA Disclosure Code).

NOVARTIS

Aggregate disclosures are limited to Research and Development ToVs and such ToVs that cannot be disclosed on an individual basis for legal reasons

Novartis Pharma AG certifies that aggregate disclosure is limited to the following topics:

- Research and Development Transfers of Value (as defined in the EFPIA Disclosure Code);
- Transfers of Value to Recipients that have opposed to the publication on grounds of the protection of their private data;
- If an HCP or HCO (where applicable) has provided consent to individual disclosure only in respect of part of the Transfers of Value he/she/it received, all Transfers of Value to such HCP or HCO (where applicable) are being disclosed in the aggregate.

Ensuring compliance with Data Privacy Obligations

The collection, processing and disclosure of transfers of value have been made in accordance with the Data Privacy laws applicable in the respective countries.

Date: 3 June 2019

Name of signatory:

Paul Hudson

Position in the Company:

Chief Executive Officer Novartis Pharma AG

Signature:

EFPIA Disclosure Code
2019 Self-Certification Scheme

Healthcare professionals (HCPs) and healthcare organisations (HCOs) with whom Novo Nordisk works provide the Pharmaceutical Industry with valuable, independent and expert knowledge derived from their clinical and management experience. As owners of scientific knowledge and experts in medicinal products, pharmaceutical companies can be a unique resource to the healthcare systems and providers, which will ultimately benefit the patients.

Throughout the medicines life cycle pharmaceutical companies work with scientists and HCPs. These collaborations are essential in addressing patient needs. Industry and HCPs collaborate in a range of activities from clinical research to sharing best clinical practice and exchanging information on how new medicines fit into the patient pathway.

EFPIA and its member associations have adopted codes and guidelines to ensure that the interactions of their member companies with HCPs and HCOs meet the high standards of integrity and transparency. Building greater transparency to the relationships between pharmaceutical companies and HCPs/HCOs aims to building understanding of the collaboration and recognition of its value to patient care.

Except in countries where disclosure is prescribed by laws, Novo Nordisk hereby confirms that its disclosures of transfers of value (ToVs) to HCPs and HCOs made in 2018 have been made to the best of its knowledge and reported in application of the EFPIA Disclosure Code following key principles:

Disclosure quality

Novo Nordisk certifies that:

- Its disclosures are made in each country where it operates;
- Its disclosures include direct and indirect ToVs, as defined in the codes and associated guidance issued by EFPIA;
- Its Methodological Note describes the process it has followed in order to compile the data hereby disclosed.

Methodology used for the collection and organisation of ToVs is in line with the EFPIA Disclosure Code's requirements and applicable codes

Novo Nordisk certifies that:

- Data collection complies with the requirements of the EFPIA Disclosure Code;
- Actions were taken to ensure individual disclosure for HCPs and HCOs' transfers of values (each as defined in the EFPIA Disclosure Code).

Aggregate disclosures are limited to Research and Development ToVs and such ToVs that cannot be disclosed on an individual basis for legal reasons

Novo Nordisk certifies that aggregate disclosure is limited to the following topics:

- Research and Development Transfers of Value (as defined in the EFPIA Disclosure Code);
- Transfers of Value to Recipients that have opposed to the publication on grounds of the protection of their private data;
- If an HCP or HCO (where applicable) has provided consent to individual disclosure only in respect of part of the Transfers of Value he/she/it received, all Transfers of Value to such HCP or HCO (where applicable) are being disclosed in the aggregate.

Ensuring compliance with Data Privacy Obligations

Novo Nordisk certifies that its disclosure complies with the Data Privacy obligations.

Date: 29.05.2019

Name of signatory:

Maziar Mike Doustdar

Position in the Company:

Executive Vice President, International Operations

Signature:

NB: This Self-Certification Scheme (Letter) will be signed by EFPIA Board members (or equivalent position if the corporate member has no representative in the EFPIA Board) and will be published on the companies' websites at the same time as the data disclosure. The Letters will also be published on the EFPIA website.

Otsuka Pharmaceutical Europe Ltd.
Gallions
Wexham Springs
Framewood Road
Wexham
SL3 6PJ
Phone: +44 (0)203 747 5000
Fax: +44 (0)1895 207115
Web: www.otsuka-europe.com
Registered in: England No: 3456326

Otsuka

Otsuka-people creating new products for better health worldwide

EFPIA Disclosure Code

2019 Self-Certification Scheme

Healthcare professionals (HCPs) and healthcare organisations (HCOs) with whom Otsuka Pharmaceutical Europe Ltd and its affiliate companies ("Otsuka") works provide the Pharmaceutical Industry with valuable, independent and expert knowledge derived from their clinical and management experience. As owners of scientific knowledge and experts in medicinal products, pharmaceutical companies can be a unique resource to the healthcare systems and providers, which will ultimately benefit the patients.

Throughout the medicines life cycle pharmaceutical companies work with scientists and HCPs. These collaborations are essential in addressing patient needs. Industry and HCPs collaborate in a range of activities from clinical research to sharing best clinical practice and exchanging information on how new medicines fit into the patient pathway.

EFPIA and its member associations have adopted codes and guidelines to ensure that the interactions of their member companies with HCPs and HCOs meet the high standards of integrity and transparency. Building greater transparency to the relationships between pharmaceutical companies and HCPs/HCOs aims to building understanding of the collaboration and recognition of its value to patient care.

Except in countries where disclosure is prescribed by laws, Otsuka hereby confirms that its disclosures of transfers of value (ToVs) to HCPs and HCOs made in 2018 have been reported in application of the EFPIA Disclosure Code following key principles:

Disclosure quality

Otsuka certifies that:

- Its disclosures are made in each country where it operates;
- Its disclosures include direct and indirect Transfers of Value, as defined in the codes and associated guidance issued by EFPIA;
- Its Methodological Note describes the process it has followed in order to compile the data hereby disclosed.

Methodology used for the collection and organisation of ToVs is in line with the EFPIA Disclosure Code's requirements and applicable codes

Otsuka certifies that:

- Data collection complies with the requirements of the EFPIA disclosure code;

Otsuka

Otsuka-people creating new products for better health worldwide

- Actions were taken to ensure individual disclosure for HCPs and HCOs' transfers of values (each as defined in the EFPIA Disclosure Code)

Aggregate disclosures are limited to Research and Development Transfers of Value and such Transfers of Value that cannot be disclosed on an individual basis for legal reasons

Otsuka certifies that aggregate disclosure is limited to the following topics:

- Research and Development Transfers of Value (as defined in the EFPIA Disclosure Code)
- Transfers of Values to Recipients that have opposed to the publication on grounds of the protection of their private data;
- Transfers of Values to Recipients, where issuing an updated Data Privacy Notice and/or Disclosure Consent will complete by 31 December 2019;
- If an HCP or HCO (where applicable) has provided consent to individual disclosure only in respect of part of the Transfers of Value he/she/it received, all Transfers of Value to such HCP or HCO (where applicable) are being disclosed in aggregate.

Ensuring compliance with Data Privacy Obligations

Otsuka certifies that its disclosure complies with Data Privacy Obligations.

Date: 28th June 2019

Name of signatory: Mel Walker

Position in the Company: Regional Vice President, Innovation, Business Development and Market Access

Signature:

Pfizer Inc.
235 East 42nd Street
New York, NY 10017-5755

Angela Hwang
Group President
Pfizer Biopharmaceuticals Group

EFPIA Disclosure Code
2019 Self-Certification Scheme

Healthcare professionals (HCPs) and healthcare organisations (HCOs) with whom Pfizer Inc. works provide the Pharmaceutical Industry with valuable, independent and expert knowledge derived from their clinical and management experience. As owners of scientific knowledge and experts in medicinal products, pharmaceutical companies can be a unique resource to the healthcare systems and providers, which will ultimately benefit the patients.

Throughout the medicines life cycle pharmaceutical companies work with scientists and HCPs. These collaborations are essential in addressing patient needs. Industry and HCPs collaborate in a range of activities from clinical research to sharing best clinical practice and exchanging information on how new medicines fit into the patient pathway.

EFPIA and its member associations have adopted codes and guidelines to ensure that the interactions of their member companies with HCPs and HCOs meet the high standards of integrity and transparency. Building greater transparency to the relationships between pharmaceutical companies and HCPs/HCOs aims to building understanding of the collaboration and recognition of its value to patient care.

Except in countries where disclosure is prescribed by laws, Pfizer Inc. hereby confirms that its disclosures of transfers of value (ToVs) to HCPs and HCOs made in 2018 have been reported in application of the EFPIA Disclosure Code following key principles:

Disclosure quality

Pfizer Inc. certifies that:

- Its disclosures are made in each country where it operates;
- Its disclosures include direct and indirect ToVs, as defined in the codes and associated guidance issued by EFPIA;
- Its Methodological Note describes the process it has followed in order to compile the data hereby disclosed.

Methodology used for the collection and organisation of ToVs is in line with the EFPIA Disclosure Code's requirements and applicable codes

Pfizer Inc. certifies that:

- Data collection complies with the requirements of the EFPIA Disclosure Code;
- Actions were taken to ensure individual disclosure for HCPs and HCOs' transfers of values (each as defined in the EFPIA Disclosure Code).

Aggregate disclosures are limited to Research and Development ToVs and such ToVs that cannot be disclosed on an individual basis for legal reasons

Pfizer Inc. certifies that aggregate disclosure is limited to the following topics:

- Research and Development Transfers of Value (as defined in the EFPIA Disclosure Code);
- Transfers of Value to Recipients that have opposed to the publication on grounds of the protection of their private data;
- If an HCP or HCO (where applicable) has provided consent to individual disclosure only in respect of part of the Transfers of Value he/she/it received, all Transfers of Value to such HCP or HCO (where applicable) are being disclosed in the aggregate.

Ensuring compliance with Data Privacy Obligations

Pfizer Inc. certifies that its disclosure complies with the Data Privacy obligations.

Date:	June 20, 2019
Name of signatory:	Angela Hwang
Position in the Company:	Group President, Pfizer Biopharmaceuticals Group
Signature:	

Pierre Fabre
Médicament

EFPIA Disclosure Code
2019 Self-Certification Scheme

Healthcare professionals (HCPs) and healthcare organisations (HCOs) with whom PIERRE FABRE MEDICAMENT works provide the Pharmaceutical Industry with valuable, independent and expert knowledge derived from their clinical and management experience. As owners of scientific knowledge and experts in medicinal products, pharmaceutical companies can be a unique resource to the healthcare systems and providers, which will ultimately benefit the patients.

Throughout the medicines life cycle pharmaceutical companies work with scientists and HCPs. These collaborations are essential in addressing patient needs. Industry and HCPs collaborate in a range of activities from clinical research to sharing best clinical practice and exchanging information on how new medicines fit into the patient pathway.

EFPIA and its member associations have adopted codes and guidelines to ensure that the interactions of their member companies with HCPs and HCOs meet the high standards of integrity and transparency. Building greater transparency to the relationships between pharmaceutical companies and HCPs/HCOs aims to building understanding of the collaboration and recognition of its value to patient care.

Except in countries where disclosure is prescribed by laws, PIERRE FABRE MEDICAMENT hereby confirms that its disclosures of transfers of value (ToVs) to HCPs and HCOs made in 2018 have been reported in application of the EFPIA Disclosure Code following key principles:

Disclosure quality

PIERRE FABRE MEDICAMENT certifies that:

- Its disclosures are made in each country where it operates;
- Its disclosures include direct and indirect ToVs, as defined in the codes and associated guidance issued by EFPIA;
- Its Methodological Note describes the process it has followed in order to compile the data hereby disclosed.

Methodology used for the collection and organisation of ToVs is in line with the EFPIA Disclosure Code's requirements and applicable codes

PIERRE FABRE MEDICAMENT certifies that:

- Data collection complies with the requirements of the EFPIA Disclosure Code;

- Actions were taken to ensure individual disclosure for HCPs and HCOs' transfers of values (each as defined in the EFPIA Disclosure Code).

Aggregate disclosures are limited to Research and Development ToVs and such ToVs that cannot be disclosed on an individual basis for legal reasons

PIERRE FABRE MEDICAMENT certifies that aggregate disclosure is limited to the following topics:

- Research and Development Transfers of Value (as defined in the EFPIA Disclosure Code);
- Transfers of Value to Recipients that have opposed to the publication on grounds of the protection of their private data;
- If an HCP or HCO (where applicable) has provided consent to individual disclosure only in respect of part of the Transfers of Value he/she/it received, all Transfers of Value to such HCP or HCO (where applicable) are being disclosed in the aggregate.

Ensuring compliance with Data Privacy Obligations

PIERRE FABRE MEDICAMENT certifies that its disclosure complies with the Data Privacy obligations.

Date: 17 JUIN 2019

Name of signatory: **Jean-Luc LOWINSKI**

Position in the Company: **President & CEO Pharmaceuticals Division**

Signature:

EFPIA Disclosure Code
2019 Self-Certification Scheme

Healthcare professionals (HCPs) and healthcare organisations (HCOs) with whom F. Hoffmann – La Roche (hereinafter "Roche") works provide the Pharmaceutical Industry with valuable, independent and expert knowledge derived from their clinical and management experience. As owners of scientific knowledge and experts in medicinal products, pharmaceutical companies can be a unique resource to the healthcare systems and providers, which will ultimately benefit the patients.

Throughout the medicines life cycle pharmaceutical companies work with scientists and HCPs. These collaborations are essential in addressing patient needs. Industry and HCPs collaborate in a range of activities from clinical research to sharing best clinical practice and exchanging information on how new medicines fit into the patient pathway.

EFPIA and its member associations have adopted codes and guidelines to ensure that the interactions of their member companies with HCPs and HCOs meet the high standards of integrity and transparency. Building greater transparency to the relationships between pharmaceutical companies and HCPs/HCOs aims to building understanding of the collaboration and recognition of its value to patient care.

Except in countries where disclosure is prescribed by laws, Roche hereby confirms that its disclosures of transfers of value (ToVs) to HCPs and HCOs made in 2018 have been reported in application of the EFPIA Disclosure Code following key principles:

Disclosure quality

Roche certifies that:

- Its disclosures are made in each country where it operates;
- Its disclosures include direct and indirect ToVs, as defined in the codes and associated guidance issued by EFPIA;
- Its Methodological Note describes the process it has followed in order to compile the data hereby disclosed.

Methodology used for the collection and organisation of ToVs is in line with the EFPIA Disclosure Code's requirements and applicable codes

Roche certifies that:

- Data collection complies with the requirements of the EFPIA Disclosure Code;
- Actions were taken to ensure individual disclosure for HCPs and HCOs' transfers of values (each as defined in the EFPIA Disclosure Code).

Aggregate disclosures are limited to Research and Development ToVs and such ToVs that cannot be disclosed on an individual basis for legal reasons

Roche certifies that aggregate disclosure is limited to the following topics:

- Research and Development Transfers of Value (as defined in the EFPIA Disclosure Code);
- Transfers of Value to Recipients that have opposed to the publication on grounds of the protection of their private data;

- If an HCP or HCO (where applicable) has provided consent to individual disclosure only in respect of part of the Transfers of Value he/she/it received, all Transfers of Value to such HCP or HCO (where applicable) are being disclosed in the aggregate.

Ensuring compliance with Data Privacy Obligations

Roche certifies that its disclosure complies with the Data Privacy obligations.

Date: 27 June, 2019

Name of signatory: Bill Anderson

Position: CEO Roche Pharmaceuticals

Signature:

Date: 24 June, 2019

Name of signatory: Padraic Ward

Position: Head of Pharma International

Signature:



SANOFI

EFPIA Disclosure Code
2019 Self-Certification Scheme

Healthcare professionals (HCPs) and healthcare organizations (HCOs) with whom Sanofi works provide the pharmaceutical industry with valuable, independent and expert knowledge derived from their clinical and management experience. As owners of scientific knowledge and experts in medicinal products, pharmaceutical companies can be a unique resource to the healthcare systems and providers, which will ultimately benefit the patients.

Throughout the medicines life cycle pharmaceutical companies work with scientists and HCPs. These collaborations are essential in addressing patient needs. Industry and HCPs collaborate in a range of activities from clinical research to sharing best clinical practice and exchanging information on how new medicines fit into the patient pathway.

EFPIA and its member associations have adopted codes and guidelines to ensure that the interactions of their member companies with HCPs and HCOs meet the high standards of integrity and transparency. Building greater transparency to the relationships between pharmaceutical companies and HCPs/HCOs aims to building understanding of the collaboration and recognition of its value to patient care.

Except in countries where disclosure is prescribed by laws, Sanofi hereby confirms that its disclosures of transfers of value (ToVs) to HCPs and HCOs made in 2018 have been reported in application of the EFPIA Disclosure Code following key principles:

Disclosure quality

Sanofi certifies that:

- Its disclosures are made in each country where it operates;
- Its disclosures include direct and indirect ToVs, as defined in the codes and associated guidance issued by EFPIA;
- Its Methodological Note describes the process it has followed in order to compile the data hereby disclosed.

Methodology used for the collection and organization of ToVs is in line with the EFPIA Disclosure Code's requirements and applicable codes

Sanofi certifies that:

- Data collection complies with the requirements of the EFPIA Disclosure Code;
- Actions were taken to ensure individual disclosure for HCPs and HCOs' transfers of values (each as defined in the EFPIA Disclosure Code).

Aggregate disclosures are limited to Research and Development ToVs and such ToVs that cannot be disclosed on an individual basis for legal reasons

Sanofi certifies that aggregate disclosure is limited to the following topics:

SANOFI

- Research and Development Transfers of Value (as defined in the EFPIA Disclosure Code);
- Transfers of Value to Recipients that have opposed to the publication on grounds of the protection of their private data;
- If an HCP or HCO (where applicable) has provided consent to individual disclosure only in respect of part of the Transfers of Value he/she/it received, all Transfers of Value to such HCP or HCO (where applicable) are being disclosed in the aggregate.

Ensuring compliance with Data Privacy Obligations

Sanofi certifies that its disclosure complies with the Data Privacy obligations.

Date: MAY 21, 2019

Name of signatory: Olivier Brandicourt

Position in the Company: Chief Executive Officer

Signature: O. Brandicourt

NB: This Self-Certification Scheme (Letter) will be signed by EFPIA Board members (or equivalent position if the corporate member has no representative in the EFPIA Board) and will be published on the companies' websites at the same time as the data disclosure. The Letters will also be published on the EFPIA website.

EFPIA Disclosure Code
2019 Self-Certification Scheme

Healthcare professionals (HCPs) and healthcare organisations (HCOs) with whom SERVIER works provide the Pharmaceutical Industry with valuable, independent and expert knowledge derived from their clinical and management experience. As owners of scientific knowledge and experts in medicinal products, pharmaceutical companies can be a unique resource to the healthcare systems and providers, which will ultimately benefit the patients.

Throughout the medicines life cycle pharmaceutical companies work with scientists and HCPs. These collaborations are essential in addressing patient needs. Industry and HCPs collaborate in a range of activities from clinical research to sharing best clinical practice and exchanging information on how new medicines fit into the patient pathway.

EFPIA and its member associations have adopted codes and guidelines to ensure that the interactions of their member companies with HCPs and HCOs meet the high standards of integrity and transparency. Building greater transparency to the relationships between pharmaceutical companies and HCPs/HCOs aims to building understanding of the collaboration and recognition of its value to patient care.

Except in countries where disclosure is prescribed by laws, SERVIER hereby confirms that its disclosures of transfers of value (ToVs) to HCPs and HCOs made in 2018 have been reported in application of the EFPIA Disclosure Code following key principles:

Disclosure quality

SERVIER certifies that:

- Its disclosures are made in each country where it operates;
- Its disclosures include direct and indirect ToVs, as defined in the codes and associated guidance issued by EFPIA;
- Its Methodological Note describes the process it has followed in order to compile the data hereby disclosed.

Methodology used for the collection and organisation of ToVs is in line with the EFPIA Disclosure Code's requirements and applicable codes

SERVIER certifies that:

- Data collection complies with the requirements of the EFPIA Disclosure Code;
- Actions were taken to ensure individual disclosure for HCPs and HCOs' transfers of values (each as defined in the EFPIA Disclosure Code).

Aggregate disclosures are limited to Research and Development ToVs and such ToVs that cannot be disclosed on an individual basis for legal reasons

SERVIER certifies that aggregate disclosure is limited to the following topics:

- Research and Development Transfers of Value (as defined in the EFPIA Disclosure Code);
- Transfers of Value to Recipients that have opposed to the publication on grounds of the protection of their private data;
- If an HCP or HCO (where applicable) has provided consent to individual disclosure only in respect of part of the Transfers of Value he/she/it received, all Transfers of Value to such HCP or HCO (where applicable) are being disclosed in the aggregate.

Ensuring compliance with Data Privacy Obligations

SERVIER certifies that its disclosure complies with the Data Privacy obligations.

Date: June 20th, 2019

Name of signatory: Mr Olivier LAUREAU

Position in the Company: President

Signature:

Name of signatory: Mrs Marie-Christine LARCHER

Position in the Company: Director Legal Compliance

Signature:

Zaehlerweg 10
6300 Zug
Switzerland
shire.com

Shire

EFPIA Disclosure Code

2019 Self-Certification Scheme

Healthcare professionals (HCPs) and healthcare organisations (HCOs) with whom Shire, now part of Takeda Pharmaceuticals International AG works provides the Pharmaceutical Industry with valuable, independent and expert knowledge derived from their clinical and management experience. As owners of scientific knowledge and experts in medicinal products, pharmaceutical companies can be a unique resource to the healthcare systems and providers, which will ultimately benefit the patients.

Throughout the medicines life cycle pharmaceutical companies work with scientists and HCPs. These collaborations are essential in addressing patient needs. Industry and HCPs collaborate in a range of activities from clinical research to sharing best clinical practice and exchanging information on how new medicines fit into the patient pathway.

EFPIA and its member associations have adopted codes and guidelines to ensure that the interactions of their member companies with HCPs and HCOs meet the high standards of integrity and transparency. Building greater transparency to the relationships between pharmaceutical companies and HCPs/HCOs aims to building understanding of the collaboration and recognition of its value to patient care.
Except in countries where disclosure is prescribed by laws, Shire part of Takeda Pharmaceuticals International AG hereby confirms that its disclosures of transfers of value (ToVs) to HCPs and HCOs made in 2018 have been reported in application of the EFPIA Disclosure Code following key principles:

Disclosure quality

Shire, now part of Takeda Pharmaceuticals International AG certifies that:

- Its disclosures are made in each country where it operates;
- Its disclosures include direct and indirect ToVs, as defined in the codes and associated guidance issued by EFPIA;
- Its Methodological Note describes the process it has followed in order to compile the data hereby disclosed.

Zaehlerweg 10
6300 Zug
Switzerland
shire.com

Methodology used for the collection and organisation of ToVs is in line with the EFPIA Disclosure Code's requirements and applicable codes

Shire, now part of Takeda Pharmaceuticals International AG certifies that:

- Data collection complies with the requirements of the EFPIA Disclosure Code;
- Actions were taken to ensure individual disclosure for HCPs and HCOs' transfers of values (each as defined in the EFPIA Disclosure Code).

Aggregate disclosures are limited to Research and Development ToVs and such ToVs that cannot be disclosed on an individual basis for legal reasons

Shire, now part of Takeda Pharmaceuticals International AG certifies that aggregate disclosure is limited to the following topics:

- Research and Development Transfers of Value (as defined in the EFPIA Disclosure Code);
- Transfers of Value to Recipients that have opposed to the publication on grounds of the protection of their private data;
- If an HCP or HCO (where applicable) has provided consent to individual disclosure only in respect of part of the Transfers of Value he/she/it received, all Transfers of Value to such HCP or HCO (where applicable) are being disclosed in the aggregate.

Ensuring compliance with Data Privacy Obligations

Shire, now part of Takeda Pharmaceuticals International AG certifies that its disclosure complies with the Data Privacy obligations.

Date: JUNE 19, 2019

Name of signatory: Giles Platford

Position in the Company: President Europe and Canada

Signature: GP

EFPIA Disclosure Code
2019 Self-Certification Scheme

Healthcare professionals (HCPs) and healthcare organisations (HCOs) with whom Takeda Pharmaceuticals International AG works provide the Pharmaceutical Industry with valuable, independent and expert knowledge derived from their clinical and management experience. As owners of scientific knowledge and experts in medicinal products, pharmaceutical companies can be a unique resource to the healthcare systems and providers, which will ultimately benefit the patients.

Throughout the medicines life cycle pharmaceutical companies work with scientists and HCPs. These collaborations are essential in addressing patient needs. Industry and HCPs collaborate in a range of activities from clinical research to sharing best clinical practice and exchanging information on how new medicines fit into the patient pathway.

EFPIA and its member associations have adopted codes and guidelines to ensure that the interactions of their member companies with HCPs and HCOs meet the high standards of integrity and transparency. Building greater transparency to the relationships between pharmaceutical companies and HCPs/HCOs aims to building understanding of the collaboration and recognition of its value to patient care.

Except in countries where disclosure is prescribed by laws, Takeda Pharmaceuticals International AG hereby confirms that its disclosures of transfers of value (ToVs) to HCPs and HCOs made in 2018 have been reported in application of the EFPIA Disclosure Code following key principles:

Takeda Pharmaceuticals International AG
Thurgauerstrasse 130
8152 Glattpark-Opfikon (Zurich), Switzerland

Disclosure quality

Takeda Pharmaceuticals International AG certifies that:

- Its disclosures are made in each country where it operates;
- Its disclosures include direct and indirect ToVs, as defined in the codes and associated guidance issued by EFPIA;
- Its Methodological Note describes the process it has followed in order to compile the data hereby disclosed.

Methodology used for the collection and organisation of ToVs is in line with the EFPIA Disclosure Code's requirements and applicable codes

Takeda Pharmaceuticals International AG certifies that:

- Data collection complies with the requirements of the EFPIA Disclosure Code;
- Actions were taken to ensure individual disclosure for HCPs and HCOs' transfers of values (each as defined in the EFPIA Disclosure Code).

Aggregate disclosures are limited to Research and Development ToVs and such ToVs that cannot be disclosed on an individual basis for legal reasons

Takeda Pharmaceuticals International AG certifies that aggregate disclosure is limited to the following topics:

- Research and Development Transfers of Value (as defined in the EFPIA Disclosure Code);
- Transfers of Value to Recipients that have opposed to the publication on grounds of the protection of their private data;
- If an HCP or HCO (where applicable) has provided consent to individual disclosure only in respect of part of the Transfers of Value he/she/it received, all Transfers of Value to such HCP or HCO (where applicable) are being disclosed in the aggregate.

Ensuring compliance with Data Privacy Obligations

Takeda Pharmaceuticals International AG certifies that its disclosure complies with the Data Privacy obligations.

Date: JUNE 19, 2019

Name of signatory: Giles Platford

Position in the Company: President Europe and Canada

Signature: 

Takeda Pharmaceuticals International AG
Thurgauerstrasse 130
8152 Glattpark-Opfikon (Zurich), Switzerland

Europe
Teva Pharmaceuticals Europe B.V.

EFPIA Disclosure Code
2019 Self-Certification Letter
Teva Pharmaceuticals Europe BV

Healthcare professionals (HCPs) and healthcare organisations (HCOs) with whom Teva Pharmaceutical Europe BV works provide the Pharmaceutical Industry with valuable, independent and expert knowledge derived from their clinical and management experience. As owners of scientific knowledge and experts in medicinal products, pharmaceutical companies can be a unique resource to the healthcare systems and providers, which will ultimately benefit the patients.

Throughout the medicines life cycle pharmaceutical companies work with scientists and HCPs. These collaborations are essential in addressing patient needs. Industry and HCPs collaborate in a range of activities from clinical research to sharing best clinical practice and exchanging information on how new medicines fit into the patient pathway.

EFPIA and its member associations have adopted codes and guidelines to ensure that the interactions of their member companies with HCPs and HCOs meet the high standards of integrity and transparency. Building greater transparency to the relationships between pharmaceutical companies and HCPs/HCOs aims to building understanding of the collaboration and recognition of its value to patient care.

Except in countries where disclosure is prescribed by laws, Teva Pharmaceutical Europe BV hereby confirms that its disclosures of transfers of value (ToVs) to HCPs and HCOs made in 2018 have been reported in application of the EFPIA Disclosure Code following key principles:

Disclosure scope:

Teva Pharmaceutical Europe BV certifies that its disclosures of ToVs:

- Have been completed in each EFPIA country where Teva Pharmaceuticals Europe BV operates,
- include direct and indirect ToVs, as defined in the codes and associated guidance issued by EFPIA as well as associated national codes/clarifications,
- are further described in the respective country's Methodological Note, and
- may contain minor discrepancies resulting from the sale, transition, and timing of marketing authorization transfers of Teva's women's health business to Theramex.

Methodology used for the collection and organisation of ToVs is in line with the EFPIA Disclosure Code's requirements and applicable codes

Teva Pharmaceutical Europe BV certifies that:

- Data collection complies with the requirements of the EFPIA Disclosure Code;
- Actions were taken to ensure individual disclosure for HCPs and HCOs' transfers of values (each as defined in the EFPIA Disclosure Code).

Teva Pharmaceuticals Europe B.V.
Piet Heinkade 107, P.O. Box 16416, 1001 RM AMSTERDAM - The Netherlands
Phone: +31(0)20 2193 000 – Fax: +31(0)20 2193 299 www.tevapharm.com

Chamber of Commerce Amsterdam 30110625, VAT NO. NL 003 973 190 B01,
Bank: ABN-AMRO IBAN: NL98 ABNA 0241487862, BIC: ABNANL2AXXX

Europe
Teva Pharmaceuticals Europe B.V.

(continued)

Aggregate disclosures are limited to Research and Development ToVs and such ToVs that cannot be disclosed on an individual basis for legal reasons

Teva Pharmaceutical Europe BV certifies that aggregate disclosure is limited to the following topics:

- Research and Development Transfers of Value (as defined in the EFPIA Disclosure Code);
- Transfers of Value to Recipients that have opposed to the publication on grounds of the protection of their private data;
- If an HCP or HCO (where applicable) has provided consent to individual disclosure only in respect of part of the Transfers of Value he/she/it received, all Transfers of Value to such HCP or HCO (where applicable) are being disclosed in the aggregate.

Ensuring compliance with data privacy obligations

Teva Pharmaceutical Europe BV also certifies that its disclosure complies with relevant data privacy obligations.

Date: June 28, 2019

Name of signatory: Richard Daniell

Position in the Company: Executive Vice President
Teva Pharmaceuticals Europe BV

Signature: 

Richard Daniell
Executive Vice President
Europe Commercial

Teva Pharmaceuticals Europe B.V.
Computerweg 10, P.O. Box 43011, 3540 AA UTRECHT - The Netherlands
Phone: +31(0)346 290 200 – Fax: +31(0)346 290 299 www.tevapharm.com

Chamber of Commerce Utrecht 30110625, VAT NO. NL 003 973 190 B01,
Bank: ABN-AMRO IBAN: NL98 ABNA 0241487862, BIC: ABNANL2AXXX

EFPIA Disclosure Code
2019 Self-Certification Scheme

Healthcare professionals (HCPs) and healthcare organisations (HCOs) with whom UCB works provide the Pharmaceutical Industry with valuable, independent and expert knowledge derived from their clinical and management experience. As owners of scientific knowledge and experts in medicinal products, pharmaceutical companies can be a unique resource to the healthcare systems and providers, which will ultimately benefit the patients.

Throughout the medicines life cycle pharmaceutical companies work with scientists and HCPs. These collaborations are essential in addressing patient needs. Industry and HCPs collaborate in a range of activities from clinical research to sharing best clinical practice and exchanging information on how new medicines fit into the patient pathway.

EFPIA and its member associations have adopted codes and guidelines to ensure that the interactions of their member companies with HCPs and HCOs meet the high standards of integrity and transparency. Building greater transparency to the relationships between pharmaceutical companies and HCPs/HCOs aims to building understanding of the collaboration and recognition of its value to patient care.

Except in countries where disclosure is prescribed by laws, UCB hereby confirms that its disclosures of transfers of value (ToVs) to HCPs and HCOs made in 2018 have been reported in application of the EFPIA Disclosure Code following key principles:

Disclosure quality

UCB certifies that:

- Its disclosures are made in each country where it operates;
- Its disclosures include direct and indirect ToVs, as defined in the codes and associated guidance issued by EFPIA;
- Its Methodological Note describes the process it has followed in order to compile the data hereby disclosed.

Methodology used for the collection and organisation of ToVs is in line with the EFPIA Disclosure Code's requirements and applicable codes

UCB certifies that:

- Data collection complies with the requirements of the EFPIA Disclosure Code;
- Actions were taken to ensure individual disclosure for HCPs and HCOs' transfers of values (each as defined in the EFPIA Disclosure Code).

Aggregate disclosures are limited to Research and Development ToVs and such ToVs that cannot be disclosed on an individual basis for legal reasons

UCB certifies that aggregate disclosure is limited to the following topics:

- Research and Development Transfers of Value (as defined in the EFPIA Disclosure Code);
- Transfers of Value to Recipients that have opposed to the publication on grounds of the protection of their private data;
- If an HCP or HCO (where applicable) has provided consent to individual disclosure only in respect of part of the Transfers of Value he/she/it received, all Transfers of Value to such HCP or HCO (where applicable) are being disclosed in the aggregate.

Ensuring compliance with Data Privacy Obligations

UCB certifies that its disclosure complies with the Data Privacy obligations.

Date: 3rd June 2019

Name of signatory: Jean-Christophe Tellier

Position in the Company: Chief Executive Officer, Chairman of the Executive Committee

Signature: